Our proprietary Probody technology
expands the opportunity for therapeutic antibodies in oncology by seeking to address a key limitation of existing antibody drugs: limited therapeutic window.
Promising classes of antibodies, including immunotherapies and antibody drug conjugates, have shown meaningful improvements in efficacy in treating cancer. However, many therapeutic antibodies may also lead to toxicities, either as single agents or combinations, as the antibody typically binds to targets on healthy tissue, not just targets on cancer cells. These toxicities can limit patients’ ability to complete a course of therapy and to achieve the full benefit of treatment.